Alder biopharmaceuticals inc (ALDR)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenues
Collaboration and license agreements

0

1,619

113

-

54,705

18,796

20,067

Operating expenses
Cost of sales

-

1,619

113

-

-

-

-

Research and development

239,108

252,902

132,760

69,611

33,439

31,883

30,669

General and administrative

47,474

38,102

26,148

16,718

12,462

7,674

7,217

Total operating expenses

286,582

292,623

159,021

86,329

45,901

39,557

37,886

Gain on license of clazakizumab

-

-

1,050

-

-

-

-

Loss from operations

-286,582

-291,004

-157,858

-86,329

8,804

-20,761

-17,819

Other income (expense)
Interest income

8,909

2,495

1,966

702

44

54

101

Interest expense

17,185

-

-

-

-

-

88

Foreign currency gain (loss)

309

223

-349

73

15

-21

-

Other income

-

50

172

84

45

158

-

Change in fair value of derivative liability

-1,658

-

-

-

-

-

-

Other expense

-

-

-

-

-

43

-

Total other income (expense), net

-9,625

2,768

1,789

859

104

148

13

Net loss before equity in net loss of unconsolidated entity

-296,207

-288,236

-156,069

-85,470

8,908

-

-

Equity in net loss of unconsolidated entity

-222

-643

-185

-

-

-

-

Net loss

-296,429

-288,879

-156,254

-85,470

8,908

-20,613

-17,806

Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature

29,460

-

-

-

-

-

-

Dividends on convertible preferred stock

6,045

-

-

-

-

-

-

Net loss applicable to common stockholders

-331,934

-288,879

-156,254

-

-

-

-

Net income (loss) per share - basic

-

-

-

-

0.43

-21.14

-19.54

Net income (loss) per share - diluted

-

-

-

-

0.30

-21.14

-19.54

Weighted average number of common shares used in net income (loss) per share - basic

-

-

-

-

20,506

975

911

Weighted average number of common shares used in net income (loss) per share - diluted

-

-

-

-

29,427

975

911

Net loss per share applicable to common stockholders - basic and diluted

-4.87

-4.95

-3.23

-2.11

-

-

-

Weighted average number of common shares used in net loss per share - basic and diluted

68,099

58,347

48,407

40,586

-

-

-